Paroxysmal Supraventricular Tachycardia Clinical Trial
Official title:
Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)
The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).
The NODE-302 study is an extension of the NODE-301 efficacy study. It is a multi-centre, open label study designed to evaluate the safety of etripamil NS 70 mg when self-administered by patients for spontaneous episodes of PSVT in an outpatient setting. All patients randomized in the NODE-301 study and who meet the inclusion and exclusion criteria of the NODE-302 study are eligible for the NODE-302 study. After each episode of PSVT, patients will have the option to continue in the NODE-302 study and manage subsequent episodes of PSVT with etripamil NS 70 mg if they do not meet any withdrawal criteria. Each episode of PSVT will be documented by an ambulatory cardiac monitoring system (CMS) that will be placed on the chest by the patient or caregiver when symptoms begin, and will record at least 5 hours of continuous ECG. The study will include a Qualification Visit, a Treatment Period(s) , a Follow-up Visit(s) ,a Final Study Visit and if necessary an Early Termination Visit if the patient withdraws from the study after taking etripamil NS 70 mg and had a Follow-up Visit, or the patient withdraws from the study and did not take etripamil NS 70 mg. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04072835 -
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
|
Phase 3 | |
| Completed |
NCT01655316 -
Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
|
Phase 4 | |
| Completed |
NCT05770921 -
Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia（PSVT）
|
N/A | |
| Active, not recruiting |
NCT05820035 -
A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia
|
N/A | |
| Not yet recruiting |
NCT06327425 -
MCG for Localization of Tachyarrhythmia's Origin
|
N/A | |
| Recruiting |
NCT05410860 -
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
|
Phase 3 | |
| Completed |
NCT03464019 -
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxymal Supraventricular Tachycardia (PSVT). NODE 301 [Part 1 and Part 2 (RAPID Study)]
|
Phase 3 | |
| Completed |
NCT03042078 -
Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia
|
N/A | |
| Completed |
NCT04215640 -
Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes
|
N/A | |
| Completed |
NCT03348436 -
Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation
|
N/A | |
| Enrolling by invitation |
NCT04952610 -
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
|
Phase 3 | |
| Recruiting |
NCT05763953 -
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
|
Phase 2 |